Navigation Menu

Clinical Trial External Search


Children (age < 18 years)
Adults (age >= 18 years)

Researcher Profile

Researcher Display

Lisa McGregor, MD, PhD

Lisa McGregor, MD, PhD

Howard O. Jr. and Jean S. Beaver Professor of Pediatric Hematology/Oncology, Department of Pediatrics
Chief, Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Cancer Institute, Pediatric Cancer Team
LMM56@psu.edu

Research Interests

  • Neoplasms
  • Child
  • Neuroblastoma
  • Pediatrics
  • Irinotecan
  • Radiotherapy
  • Young Adult
  • Gefitinib
  • Survival
  • Pharmacokinetics
  • Wilms Tumor
  • Oxaliplatin

Clinical Trials

NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Renal Tumor Classification, Biology, and Banking Study
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed or Refractory Solid Tumors or Hematologic Malignancies
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3Inhibitor Gilteritinib for Patients with FLT3 Mutations
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Neuroblastoma Biology Studies
Umbrella Long-term Follow-up Protocol
Phase 1/2 Study to Evaluate Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide or in Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
A Safety, Pharmacokinetic and Efficacy Study of a ;-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy Followed by Maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532, Randomized Phase 3 Trial of Accelerated vs Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastic Germ Cell Tumors

Recent Publications

2023

Caru, M, Alberts, NM, Freeman, MC, Dandekar, SC, Rao, P, McKeone, DJ, Brown, VI, McGregor, LM & Schmitz, KH 2023, 'Chronic pain in children and adolescents diagnosed with cancer: the challenge of mitigating the pain and the potential of integrating exercise into pain management', Supportive Care in Cancer, vol. 31, no. 4, 228. https://doi.org/10.1007/s00520-023-07695-6

2022

Caru, M, Levesque, A, Rao, P, Dandekar, S, Terry, C, Brown, V, McGregor, L & Schmitz, K 2022, 'A scoping review to map the evidence of physical activity interventions in post-treatment adolescent and young adult cancer survivors', Critical Reviews in Oncology/Hematology, vol. 171, 103620. https://doi.org/10.1016/j.critrevonc.2022.103620

2020

Santana, VM, Sahr, N, Tatevossian, RG, Jia, S, Campagne, O, Sykes, A, Stewart, CF, Furman, WL & McGregor, LM 2020, 'A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors', Cancer, vol. 126, no. 8, pp. 1749-1757. https://doi.org/10.1002/cncr.32722
Rao, P, Segel, JE, McGregor, LM, Lengerich, EJ, Drabick, JJ & Miller, B 2020, 'Attendance at National Cancer Institute and Children's Oncology Group Facilities for Children, Adolescents, and Young Adults with Cancer in Pennsylvania: A Population-Based Study', Journal of Adolescent and Young Adult Oncology, vol. 9, no. 1, pp. 47-54. https://doi.org/10.1089/jayao.2019.0045